Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q305555> ?p ?o }
Showing triples 1 to 34 of
34
with 100 triples per page.
- Q305555 subject Q8493060.
- Q305555 abstract "Abarelix (trade name Plenaxis) is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available.It was originally marketed by Praecis Pharmaceuticals as Plenaxis, and is now marketed by Speciality European Pharma in Germany after receiving a marketing authorisation in 2005.".
- Q305555 atcPrefix "L02".
- Q305555 atcSuffix "BX01".
- Q305555 casNumber "183552-38-7".
- Q305555 chEBI "337298".
- Q305555 drugbank "DB00106".
- Q305555 fdaUniiCode "W486SJ5824".
- Q305555 iupacName "acetyl-D-β-naphthylalanyl- D-4-chlorophenylalanyl-D-3-pyridylalanyl-L-seryl-L- N-methyl- tyrosyl-D-asparagyl-L-leucyl-L-N(e )-isopropyl-lysyl-L-prolyl-D-alanyl-amide".
- Q305555 pubchem "16131215".
- Q305555 thumbnail Abarelix.svg?width=300.
- Q305555 wikiPageWikiLink Q1318776.
- Q305555 wikiPageWikiLink Q14864006.
- Q305555 wikiPageWikiLink Q162555.
- Q305555 wikiPageWikiLink Q181257.
- Q305555 wikiPageWikiLink Q3618379.
- Q305555 wikiPageWikiLink Q432083.
- Q305555 wikiPageWikiLink Q8493060.
- Q305555 atcPrefix "L02".
- Q305555 atcSuffix "BX01".
- Q305555 casNumber "183552".
- Q305555 chebi "337298".
- Q305555 drugbank "DB00106".
- Q305555 iupacName "acetyl-D-β-naphthylalanyl- D-4-chlorophenylalanyl-D-3-pyridylalanyl-L-seryl-L- N-methyl- tyrosyl-D-asparagyl-L-leucyl-L-N-isopropyl-lysyl-L-prolyl-D-alanyl-amide".
- Q305555 pubchem "16131215".
- Q305555 unii "W486SJ5824".
- Q305555 type ChemicalSubstance.
- Q305555 type Drug.
- Q305555 type ChemicalObject.
- Q305555 type Thing.
- Q305555 type Q8386.
- Q305555 comment "Abarelix (trade name Plenaxis) is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available.It was originally marketed by Praecis Pharmaceuticals as Plenaxis, and is now marketed by Speciality European Pharma in Germany after receiving a marketing authorisation in 2005.".
- Q305555 label "Abarelix".
- Q305555 depiction Abarelix.svg.